Navigation Links
NACDS Opinion Piece Urges Drug-Abuse Prevention Bill Sensitive to Chronic Pain Patients’ Needs
Date:4/16/2019

The Hill published an opinion piece by National Association of Chain Drug Stores (NACDS) President & CEO Steven C. Anderson, IOM, CAE, that urges enactment of legislation to help reduce opioid addiction and abuse, while maintaining medication access for those in need of the medications for chronic pain, cancer, other diseases, and end-of-life care.

The opinion piece, published on Sunday, April 14, urges support for the John S. McCain Opioid Addiction and Prevention Act (S. 724/H.R. 1614), introduced by U.S. Sen. Kirsten Gillibrand (D-NY), U.S. Sen. Cory Gardner (R-CO), U.S. Rep. John Katko (R-NY) and U.S. Rep. Thomas R. Suozzi (D-NY). The bill would limit to a seven-day supply a first prescription of opioids for temporary, or acute, pain – such as that associated with a broken bone.

The legislation is consistent with the Centers for Disease Control and Prevention’s (CDC) guidelines for prescribing opioids, which state that, for acute pain, “three days or less will often be sufficient; more than seven days will rarely be needed.” The legislation would not prevent a prescriber from issuing another prescription after the first one to address a patient’s needs.

Anderson wrote: “The national discussion of opioid-related issues can resemble a pendulum. It swings to a focus on the sincere needs of patients suffering with excruciating chronic pain. It then swings to address the desperate pleas of communities and families who have tragically lost loved ones to drug abuse and addiction.

“The victims deserve more than a pendulum-approach to policymaking and publicity. They deserve a comprehensive approach to a complex dilemma, that – at the same time – addresses everyone’s needs.”

From that perspective, Anderson described the role of S. 724/H.R. 1614 as part of a far-reaching approach to the issue: “[the bill] essentially would establish a ‘safety’ mechanism for the use of opioids in the management of acute pain.”

While the opinion piece notes that the legislation should not be considered a panacea, but rather part of a comprehensive effort, it also notes the complexities of the current state of drug abuse. Anderson described the substantial impact of illegally made and trafficked fentanyl and heroin.

NACDS emphasizes that the seven-day limit for initial acute-pain opioid prescriptions is consistent with pharmacists' recommendations from the front-lines of care, their collaboration with law enforcement, and the needs of chronic pain sufferers. Six-in-10 Americans support this measure, with only two-in-10 indicating opposition, according to a January 2019 Morning Consult poll commissioned by NACDS.

NACDS noted that the opinion research reflects consistent support for this strategic approach across political ideologies, and that support is particularly strong among seniors. Further, seven-in-10 voters support “advancing policies that leverage pharmacies’ role as working partners for stronger and safer communities – such as working to address the opioid-abuse epidemic.”

The bill is consistent with one of NACDS’ priority public policy recommendations to help further address the opioid abuse epidemic. NACDS’ recommendations relate to initial-prescription limits for acute pain; prescription drug monitoring plans (PDMP); drug disposal; and mandatory electronic prescribing.

The legislation would build on the SUPPORT for Patients and Communities Act (H.R. 6), enacted in 2018, which is consistent with all of NACDS’ recommendations and which was particularly helpful in requiring electronic prescribing for Schedule II through V controlled substances prescriptions covered under Medicare Part D to help prevent fraud, abuse and waste – with limited exceptions to ensure patient access.

The legislation also is consistent with the White House’s 2019 National Drug Control Strategy, which NACDS welcomed in February.

In addition to advancing its public policy recommendations, NACDS and pharmacies maintain longstanding and ongoing initiatives to prevent opioid abuse, including compliance programs; drug disposal; patient education; security initiatives; fostering naloxone access; stopping illegal online drug-sellers and rogue clinics; and more.

NACDS’ Chain Pharmacy Community Engagement Report indicates that opioid abuse prevention stands as one of the top priorities for NACDS members among their community engagement initiatives.

Editor’s Note: State-specific and Congressional-District-specific opinion research data are available on an NACDS dashboard.

Read the full story at https://www.prweb.com/releases/nacds_opinion_piece_urges_drug_abuse_prevention_bill_sensitive_to_chronic_pain_patients_needs/prweb16247060.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Seeking a Third Opinion Led this Pennsylvania Couple to Treatment that Made Their Dreams of Parenthood Finally a Reality
2. The Public Opinion in the Legal Cannabis Industry
3. NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader
4. Precision Image Analysis Adds World-Recognized Opinion Leader in Cardiac Imaging on Scientific Advisory Board
5. CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
6. Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
7. Rock Creek Pharmaceuticals Announces the Addition of Key Opinion Leaders to Enhance Dermatological Disease Program
8. Ablative Solutions Adds Key Opinion Leader to its Scientific Advisory Board
9. EU mHealth Market Conditions Benchmarking Study 2015 - Opinions on EU mHealth app market conditions of 4,400+ mHealth practitioners
10. Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
11. AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2019)... ... April 17, 2019 , ... ... Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics’ ... alike. , Through years of experience helping sponsors manage complex oncology trials, ...
(Date:4/17/2019)... ... April 17, 2019 , ... Kennywood ... or on the autism spectrum, have an amazing experience. As part of this ... awarded by the International Board of Credentialing and Continuing Education Standards (IBCCES) to ...
(Date:4/17/2019)... ... 2019 , ... NanoFUSE Biologics announced today that ... place on Thursday, March 28, 2019 at Mary Immaculate Hospital in Newport News, ... on a 71-year-old male patient. , NanoFUSE Biologics is the only bioactive ...
Breaking Medicine Technology:
(Date:4/18/2019)... ... April 18, 2019 , ... Arnet ... concentration, memory, relaxation and restful sleep to support a healthy mind and body. ... mental clarity, focus and vitality. , The portfolio includes a total of ten ...
(Date:4/18/2019)... MCLEAN, Va. (PRWEB) , ... April 18, 2019 ... ... available when selecting the best provider for their care. Through the rise of ... expect a greater level of interaction and transparency when making important purchasing decisions ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... a Korean company located in Gwangju, Korea, and has highly evaluated and confirmed ... The two companies were in discussion of a potential partnership since then. ...
(Date:4/17/2019)... ... 2019 , ... An upcoming episode of Innovations with Ed ... scheduled to air 3Q 2019 on FOX Business. Check your local listings for ... Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to developing advanced ...
(Date:4/17/2019)... ... April 17, 2019 , ... Tune in Wednesday, April 17, at 7pm ... infertility and endometriosis with robotic surgery. Hosts Dr. Jonathan Zaidan, MD, FACOG, President ... patients and the impact robotic surgery can have on a woman’s fertility, whether it ...
Breaking Medicine News(10 mins):